Literature DB >> 25001093

Prognostic factors and oncological outcomes of 122 head and neck soft tissue sarcoma patients treated at a single institution.

Jin Taek Park1, Jong-Lyel Roh, Seon-Ok Kim, Kyung-Ja Cho, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim.   

Abstract

BACKGROUND: Head and neck soft tissue sarcomas (HNSTS) are rare tumors with various histological types displaying different clinical behavior. As a result, prognostic factors of this disease remain unclear. The aim of this study was to investigate the prognostic factors and oncological outcomes of HNSTS.
MATERIALS AND METHODS: This retrospective study included 122 patients with HNSTS who were treated at our institution between 1995 and 2012. Univariate and multivariate analyses using the Cox proportional hazards model were used to determine clinicopathologic characteristics associated with locoregional control (LRC), disease-specific survival (DSS), and overall survival (OS).
RESULTS: Rhabdomyosarcoma was the most common tumor type (20 %), followed by dermatofibrosarcoma protuberance (13 %) and angiosarcoma (12 %). In a follow-up of 72 months, the 5-year LRC, DSS, and OS rates were 76, 77, and 75 %, respectively. Univariate analyses showed that age (>60 years), tumor size (>10 cm), nodal metastasis, and overall stage were significant prognostic factors for LRC, DSS, and OS (p < 0.05). Histological grade was also significantly associated with DSS (p = 0.012) and OS (p = 0.002). In multivariate analysis, tumor size and nodal metastasis were independent prognostic factors for LRC (p < 0.05), while age, histological grade, and nodal metastasis remained independent variables for both DSS and OS (p < 0.05).
CONCLUSIONS: Our data support that surgical excision of HNSTS contributes to acceptable survival rates. Several factors at diagnosis may be independently associated with recurrence and survival outcomes, and identification of these factors may help in selecting at-risk patients.

Entities:  

Mesh:

Year:  2014        PMID: 25001093     DOI: 10.1245/s10434-014-3870-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?

Authors:  Luca Bertero; Federica Massa; Jasna Metovic; Roberto Zanetti; Isabella Castellano; Umberto Ricardi; Mauro Papotti; Paola Cassoni
Journal:  Virchows Arch       Date:  2017-12-05       Impact factor: 4.064

Review 2.  Overview of the 8th Edition TNM Classification for Head and Neck Cancer.

Authors:  Shao Hui Huang; Brian O'Sullivan
Journal:  Curr Treat Options Oncol       Date:  2017-07

3.  Nomograms Predict Overall Survival and Cancer-Specific Survival in Patients with Fibrosarcoma: A SEER-Based Study.

Authors:  Guang-Heng Xiang; Juan-Juan Zhu; Chen-Rong Ke; Yi-Min Weng; Ming-Qiao Fang; Si-Pin Zhu; Yu-An Li; Jian Xiao; Lei Xu
Journal:  J Oncol       Date:  2020-09-26       Impact factor: 4.375

4.  Angiosarcoma of the Face: A Case Study and Literature Review of Local and Metastatic Angiosarcoma.

Authors:  Hugo Lara-Martinez; Molly Weinberg; Praneeth Baratam; Jeffrey Horn; Kristine Ward; Michael Styler
Journal:  Case Rep Oncol Med       Date:  2021-07-01

Review 5.  Patient and Tumour Characteristics of Adult Head and Neck Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis.

Authors:  Sakshi Andersen; Henriette Mann; Anders Krarup-Hansen; Christel Bræmer Lajer; Christian Grønhøj
Journal:  Sarcoma       Date:  2019-05-22

6.  Pretreatment tumor sampling and prognostic factors in patients with soft-tissue sarcoma of the head and neck.

Authors:  Johan H Roos; Antti A Mäkitie; Jussi Tarkkanen; Taru T Ilmarinen
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-11-12       Impact factor: 3.236

7.  Head and Neck Soft Tissue Sarcomas Treated with Radiation Therapy.

Authors:  Lucas K Vitzthum; Lindsay C Brown; Jessica W Rooney; Robert L Foote
Journal:  Rare Tumors       Date:  2016-06-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.